Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 53

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 53
---
 our definitive proxy statement filed in 2024; and (ii) one late Form 3 reporting ownership of common stock and options and one late Form 4 reporting two transactions forAdrian Quartel, M.D., FFPM.

<div align='center'>52</div>

GENERAL As a smaller reporting company, we are eligible to follow the reduced disclosure obligations regarding executive compensation that apply to smaller reporting companies. In the discussion set forth below, we provide an overview and analysis of the compensation awarded to or earned by our named executive officers (“NEOs”) identified in the 2024 Summary Compensation Table below during the fiscal year ending December 31, 2024, including the elements of our compensation program for NEOs, material compensation decisions made under that program for that fiscal year and the material factors considered in making those decisions. For the fiscal year ended December 31, 2024, our NEOs, which consisted of our principal executive officer and our two other most highly compensated executive officers for the fiscal year 2024, are listed below:

| • |     | Neil F. McFarlane, President, Chief Executive Officer and Director; |

| • |     | Adrian Quartel, M.D., FFPM, Chief Medical Officer; and |

| • |     | R. LaDuane Clifton, MBA, CPA, Chief Financial Officer and Treasurer. |

Stockholder Advisory Vote on Executive Compensation At our 2024 Annual Meeting of Stockholders, our stockholders voted in a non-binding,advisory vote to approve the compensation of our NEOs. The Compensation Committee and the full Board carefully evaluated the results and the feedback received, which they also discussed with the Compensation Committee’s compensation consultant. Subsequently, the Compensation Committee and the Board took steps to further strengthen alignment between Company performance and pay for our executive team, including Mr. McFarlane, our Chief Executive Officer. In particular, in February 2025, we awarded Mr. McFarlane performance-based restricted stock units that are eligible to vest based on the achievement of revenue goals (subject to Mr. McFarlane’s continued employment), which is designed to drive stockholder value and better align executive pay with performance. By introducing a performance-based equity award as an element of Mr. McFarlane’s compensation, our Board and Compensation Committee sought to ensure a stronger linkage between Company performance and pay for our Chief Executive Officer. EXECUTIVE SUMMARY Compensation Highlights : Base Salaries:We made modest adjustments to base salaries in 2024 based on our review of our